Pacira BioSciences Comments on Exparel Patent Litigation Ruling by the U.S. District Court for the District of New Jersey Page 1

TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has ruled that the Company’s U.S. Patent No. 11,033,495 (the ‘495 Patent) is invalid.

“We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus infringes our patents,” said Frank D. Lee, CEO of Pacira BioSciences. “In light of the court’s decision, we are considering our legal options, including pursuing appellate review in the U.S. Court of Appeals for the Federal Court, if warranted.”